Novo CEO Sees No Major Business Changes From Drug-Pricing Rules
CEO Mike Doustdar said he does not expect major changes to Novo Nordisk’s business from tougher U.S. drug-pricing regulations after the Democrats’ midterm victory.
Related stories
Scotiabank to announce fourth-quarter 2026 results
Scotiabank says it will announce its fourth-quarter results on Wednesday, Dec. The announcement date is incomplete in the source.
M impact | EQUITY | Nov 04, 2026, 02:00 PM UTC
Voyager Technologies Wins $35M NASA HUNCH Management Contract
Voyager Technologies was awarded a five-year contract to manage NASA’s HUNCH program, extending a role it has held since 2021.
M impact | EQUITY | Nov 04, 2026, 02:00 PM UTC
NHPC Q2 consolidated revenue from operations at 44.83 billion rupees
M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC
MGE Energy Reports Q3 2026 Operating Revenue of $190.4 Million
M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC
US Equity Futures Rise Pre-Bell as Traders Assess Midterm Election Results
US equity futures rose before the bell as traders assessed the implications of a Democratic win in the US midterm elections.
M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC
NHPC Reports Q2 Consolidated Net Profit of 15.49 Billion Rupees
M impact | EQUITY | Nov 04, 2026, 01:59 PM UTC